Mercks revenue from Keytruda in the Oct 17 quarter was US$1billion, so extrapolating the yearly revenue will be US$4billion so if Cavatak makes Keytruda 10% more sales Merck will have made their money in a year (give or take the cost of finalizing the approvals). Given that Cavatak actually showed better efficacy and safety profiles in 2015 than their product this valuation seems cheap.
- Forums
- ASX - By Stock
- VLA Valuation
Mercks revenue from Keytruda in the Oct 17 quarter was...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add VLA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online